Recent

% | $
Quotes you view appear here for quick access.

Hanwha SolarOne Co., L.Ş. Message Board

doc.science13000 13 posts  |  Last Activity: Jun 12, 2015 7:03 AM Member since: Dec 18, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • doc.science13000 by doc.science13000 Jun 12, 2015 7:03 AM Flag

    Does anyone have the information for the law firm handling the shareholder lawsuit? I signed up, but somehow lost there info and wanted to check on the status on that. I would think its been about 18 months since it was filed.

    Sentiment: Strong Sell

  • doc.science13000 by doc.science13000 May 29, 2015 2:52 AM Flag

    Opexa CEO Warma also discussed a personalized T-cell immunotherapy platform for autoimmune disease. The therapy is custom tailored to patients; hopefully making it an effective way to treat the disease. They also talked about a company owned and scalable eGMP manufacturing facility, and the fact that OPXA now holds 98 domestic patents.

    Validation – Finally, Warma discussed validation the company has received validation with regard to Tcelna for SPMS through a potential partnership with Merck Serono and the fact that the company has received FDA Fast Track Designation for the approval of the treatment.

    Sentiment: Strong Buy

  • doc.science13000 by doc.science13000 May 29, 2015 2:48 AM Flag

    When it comes to the company’s pipeline, there was a big announcement made today. First off, Tcelna, the company’s prime candidate not only has very limited competition, but is currently in Phase 2b for secondary progressive multiple sclerosis (SPMS) and has an overall market potential around $7 billion. The company also announced an addition to their pipeline known as OPX-212; which they hope will prove to be an effective treatment for neuromyelitis optica, an ailment with no approved therapies at the moment. That makes OPX-212 the first treatment in the Opexa Therapeutics pipeline on the orphan indication side of the fence.

    Sentiment: Strong Buy

  • doc.science13000 doc.science13000 May 19, 2015 9:21 AM Flag

    Exactly,there is a 99% chance GS already has there position. Thats why the stock fell the day after earnings as they shorted it and then got in around $2.75-$2.80. Now the stock is back at $3 where it was at during earnings and by the time the public knows about GS position it will be at $5-$6. Thats when all these message board individual traders will buy in. The only way to win on Wall St is to buy low now and sell high later on the news. Not the other way around.

    Sentiment: Strong Buy

  • Reply to

    GS Analyst very impressed with BIOC.

    by doc.science13000 May 12, 2015 11:25 PM
    doc.science13000 doc.science13000 May 13, 2015 10:11 AM Flag

    I see them licensing their products overseas and getting a licensing fee plus royalties while continuing to develop new liquid exams. Since they have a few patents they could also be brought out by a bigger biotech. They have $19 million in cash and there market cap is only around $54 million. Thats only valuing there business at $34 million when liquid biopsy market is potentially worth billions. The next pr should take us to $5-6 range.

    Sentiment: Strong Buy

  • Reply to

    GS Analyst very impressed with BIOC.

    by doc.science13000 May 12, 2015 11:25 PM
    doc.science13000 doc.science13000 May 13, 2015 7:40 AM Flag

    He asked some very important questions about IP, overseas expansion and expanding there sales to managed healthcare. Obviously, the guy could have been a foreigner with slight accent but anyway that doesn't matter. What matters is that BIOC is heading in the right direction and pps will soon follow.

    Sentiment: Buy

  • doc.science13000 by doc.science13000 May 12, 2015 11:25 PM Flag

    During the CC yesterday the analyst from GS seemded to be very impressed with the CEO' s response to his questions. Im sure they will open a position soon if not already. By the time the public knows GS and other hedgefunds have brought large positions they will be buying those shares back at $10 and above. Thats how it works in the market. I was impressed as well and look forward to the company's next achievements.

    Sentiment: Strong Buy

  • doc.science13000 by doc.science13000 May 6, 2015 7:10 AM Flag

    Has a nice pipe line of products, but could use the help from a major pharmaceutical company that has greater scale and deeper pockets. Also, currently working with only one POP network provider that has 19 million subscribers so they have plenty of room to grow here. Will be interesting to see the new institutional investors next week after the CC. Looking to pop over $5 soon.

    Sentiment: Buy

  • Reply to

    The next VLTC!!

    by doc.science13000 Apr 22, 2015 3:08 AM
    doc.science13000 doc.science13000 Apr 22, 2015 6:58 AM Flag

    Atleast $6-7 in the next 3 weeks. maybe it will hit the $8-10 range, but its safe to say at least $6-7 leading up to earnings and any announcements of new partnerships or plans to go private etc.

  • doc.science13000 by doc.science13000 Apr 22, 2015 3:08 AM Flag

    It has the same price trajectory and technicals as Voltari but even higher revenues. The stock is in the early stages of its upcoming huge run. It has over $200 million in tax loss credits which would be huge to a strategic buyer with deep pockets. Thats the same reason that makes Voltari so valuable not their #$%$ digital market platform which has less revenue than VGGL. Also, their subsidiary Wetpaint is worth more than the entire market cap. Definitely heading to $4-5 range within the next week.

    Sentiment: Buy

  • doc.science13000 by doc.science13000 Apr 20, 2015 12:28 AM Flag

    The SPA is a terrible deal for shareholders as they face massive dilution. To sell the 40 MW of storage systems is one thing, but why agree to the SPA and at a 25% discount prior to the announcement. The buyer already made a few million off there purchase as of the current market cap. ZBB mgmt. Is the worst. They should have just focused on selling the systems and using Lotte to make them if they dont have the financial means to deliver.

    Sentiment: Hold

  • doc.science13000 by doc.science13000 Apr 19, 2015 12:10 PM Flag

    This stock is way undervalued with subsidiary Wetpaint valued at $40 and its current market cap at less than that. The company has sufficient funding for the next 12 months with the $7 million from Preffered C just sold and the expected $10 million coming from the 25% sale of Wetpaint. Also, Yahoo, FourSquare or any other media company could easily buy it cheap to bolster its mobile platform. Earnings in the next 2-3 weeks should definitely move it close the $4 range. The fundamentals here are much better than Voltari Holdings and look at that stock price movement.

    Sentiment: Strong Buy

  • Reply to

    ANOTHER CHINESE ORDER

    by jeff5tg Apr 10, 2015 9:54 AM
    doc.science13000 doc.science13000 Apr 14, 2015 4:14 AM Flag

    Hi Miss Jeff. Cant believe your still trolling this company. I thought you and Moosehead fell off a cliff. Anyway, as you can see there still around. LOL!!

    Sentiment: Hold

HSOL